A new ingredient means new formulations, potentially new textures
For twenty-five years, the sunscreen aisle offered Americans the same narrow set of chemical shields against the sun — a stillness that ended this week when the FDA approved bemotrizinol, the first new sunscreen ingredient cleared for consumer use since the late 1990s. The long wait was not neglect but deliberation: the agency's demanding safety standards reflect a considered belief that what we apply to our skin, day after day across a lifetime, deserves uncommon scrutiny. The approval arrives as melanoma rates continue their slow climb, and it carries with it the quiet hope that better protection, more willingly used, might bend that curve.
- After a quarter century without a new option, American sunscreen shelves are finally changing — bemotrizinol is now cleared for use in U.S. consumer products.
- The 25-year gap wasn't regulatory failure; it was the friction of a system designed to ensure that broad, repeated skin exposure carries no hidden long-term cost.
- Bemotrizinol had already earned trust in international markets, offering broad-spectrum UVA and UVB protection with a chemical profile that may suit sensitive skin — but none of that counted until U.S. safety data satisfied the FDA.
- Dermatologists see this as more than a new ingredient — new textures and formulations could make sunscreen easier to wear consistently, directly affecting skin cancer prevention.
- The real question now is whether this approval is a door opening or a single exception, as other internationally used sunscreen compounds still await their turn in the American regulatory queue.
For more than twenty-five years, Americans choosing sunscreen have reached for products built from the same small set of active ingredients. That changed this week when the FDA approved bemotrizinol — the first new sunscreen compound cleared for U.S. consumer use since the late 1990s.
The long gap reflects something deliberate about how the agency treats sunscreen. Unlike most over-the-counter products, sunscreen is applied directly to skin, in quantity, across a lifetime. The FDA demands proof not only that an ingredient blocks UV radiation, but that it is safe for sustained human use — a high bar that slows innovation while filtering out harm. Bemotrizinol had to clear studies on skin absorption, accumulation in the body, and safety at varying concentrations before American regulators were satisfied.
The compound had already been used in sunscreens abroad for years, offering broad-spectrum protection against both UVA and UVB rays, with a chemical structure some dermatologists consider gentler on sensitive skin. Its international track record helped build the case, but approval required meeting FDA's own standards on its own terms.
The practical stakes are real. Melanoma rates have been rising in the United States for decades, and sunscreen remains one of the most effective preventive tools available — when people actually use it. New ingredients enable new formulations: different textures, finishes, and feels that may make daily application more appealing. They also expand the competitive landscape for manufacturers, which tends to drive broader innovation.
Whether this approval marks a turning point depends on what comes next. Other sunscreen ingredients used internationally are still waiting for U.S. clearance. If bemotrizinol's path through the FDA signals a willingness to move on those compounds, the sunscreen aisle may look meaningfully different within a few years. If not, this week's news will stand as a welcome but isolated development.
For more than a quarter century, Americans shopping for sunscreen have had essentially the same handful of active ingredients to choose from. That changed this week when the Food and Drug Administration gave its approval to bemotrizinol, a chemical compound that will now be permitted in sunscreens sold across the United States. It marks the first time since the late 1990s that the agency has cleared a new sunscreen ingredient for use in consumer products.
The gap itself tells a story about how the FDA approaches safety. Sunscreen is not like most other over-the-counter products. Because people apply it directly to their skin, often in large quantities and repeatedly throughout their lives, the agency treats new formulations with considerable caution. Every ingredient must clear a high bar: manufacturers must demonstrate not only that it works to block ultraviolet radiation, but that it is safe for long-term use on human skin. That scrutiny, while it protects consumers, also means the approval process moves slowly.
Bemotrizinol had been used in sunscreens in other countries for years before American regulators took it up. The compound offers broad-spectrum protection—blocking both UVA and UVB rays—and it has a chemical structure that some dermatologists believe may be gentler on sensitive skin than certain existing options. But none of that mattered until the FDA was satisfied with the safety data. The company seeking approval had to submit extensive testing, including studies on how the ingredient behaves when absorbed through skin, whether it accumulates in the body over time, and what happens at various concentrations.
Dr. Céline Gounder, CBS News's medical correspondent, has reported on the approval and the reasons behind the long wait. The rigorous standards that delayed bemotrizinol's entry into the American market are the same standards that have kept unsafe or ineffective ingredients out. That trade-off—innovation moving at a measured pace in exchange for consumer protection—reflects a deliberate choice about what the FDA's role should be.
The practical effect of this approval is that consumers now have another tool in the fight against skin cancer. Melanoma rates have been climbing in the United States for decades, and dermatologists have long emphasized that broad-spectrum sunscreen, applied generously and reapplied regularly, is one of the most effective preventive measures available. A new ingredient means new formulations, potentially new textures and finishes that might encourage people to use sunscreen more consistently. It also means manufacturers can now compete on a wider palette of chemical options, which often drives innovation in other areas—water resistance, stability, cosmetic elegance.
What happens next will likely depend on whether other companies move to develop their own bemotrizinol-based products, and whether the FDA's approval of this ingredient signals a willingness to move faster on other sunscreen compounds that have been waiting in the queue. There are other ingredients used internationally that have not yet been approved in the United States. Whether bemotrizinol's clearance opens a door or remains an isolated event will become clear over the next few years.
Notable Quotes
The FDA treats sunscreen differently than most other over-the-counter products because it goes directly on skin and stays there— Dr. Céline Gounder, CBS News medical correspondent
The Hearth Conversation Another angle on the story
Why did it take 25 years for a new sunscreen ingredient to get approved?
The FDA treats sunscreen differently than most other over-the-counter products because it goes directly on skin and stays there. They need to see evidence not just that it works, but that it's safe for lifelong use—absorption studies, accumulation data, the whole picture.
So bemotrizinol was already being used elsewhere?
Yes, in other countries for years. But that doesn't matter to the FDA. They run their own evaluation. The company had to prove safety from scratch, essentially, by American standards.
What makes bemotrizinol different from what we already have?
It offers broad-spectrum protection—both UVA and UVB—and some dermatologists think it may be easier on sensitive skin than certain existing ingredients. But the real difference is that it's new, which means new formulations, new textures, new options.
Does this approval mean the FDA will move faster on other ingredients?
That's the open question. There are other ingredients used internationally that are still waiting. Whether bemotrizinol's approval signals a shift or remains an outlier will tell us a lot about where the FDA is headed.
Why does this matter for skin cancer prevention?
More options mean more people might actually use sunscreen consistently. If someone finds a formulation they like—a texture, a finish—they're more likely to apply it regularly. And consistent use is what actually prevents melanoma.